Intravenous Administration of Nicotinamide Adenine Dinucleotide Significantly Reduces Self Report Craving Ratings Associated with Opiate and Alcohol Withdrawal.

Slides:



Advertisements
Similar presentations
Dosing and patient management requirements during induction, stabilization, and detoxification with buprenorphine Matthew A. Torrington MD Clinical Research.
Advertisements

Substance Use: Substance use comparisons included lifetime and past 30 day use (Figure 3) and lifetime use. For past 30 day use, more men reported heroin.
Swinomish Wellness Program
Journal Club Alcohol, Other Drugs, and Health: Current Evidence March–April 2009.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence November–December 2009.
Challenges and Successes Treating Adolescent Substance Use Disorders Janet L. Brody, Ph.D. Center for Family and Adolescent Research (CFAR), Oregon Research.
Role of Medications in Recovery and the Prevention of Relapse Mark Publicker, MD FASAM Medical Director, Mercy Recovery Center, Westbrook Maine.
November 16, 2012Harm Reduction Conference1 Cannabis as a facilitator of mindfulness: Implications for the treatment of addiction. Amanda Reiman, PhD MSW.
By: Shawn Thomas & Prannoy Kaushal. Mental Health Facility Trilogy Behavior Inc. Healthcare 1400 W. Greenleaf, Chicago, IL
® Introduction Low Back Pain Remedies and Procedures: Helpful or Harmful? Lauren Lyons, Terrell Benold, MD, Sandra Burge, PhD The University of Texas Health.
Diagnosis And Treatment Of Prescription Opioid Dependence Steven W. Clay, D.O. Associate Professor, Department of Family Medicine Ohio University College.
Frequency and type of adverse events associated with treating women with trauma in community substance abuse treatment programs T. KIlleen 1, C. Brown.
NIDA Grants: U10DA015831, K24DA022288, U10DA020024, K23DA022297, U10DA Predictors of Outcome in the Multi-Site CTN Prescription Opioid Addiction.
American Association for the Treatment of Opioid Dependence, Inc National Conference, Atlanta April 25, 2006 Evaluation of the Impact of Opioid Treatment.
Results of the Vivitrol Pilot in Los Angeles County Presented by: Desiree A. Crevecoeur-MacPhail, Ph.D. Research Psychologist, UCLA ISAP.
Amany M. Shebl Professor Of Medical-surgical Nursing Dean. Nursing Faculty, Mansoura University, Egypt.
Obtaining housing associated with achieving abstinence after detoxification in adults with addiction Tae Woo Park, Christine Maynié-François, Richard Saitz.
Recovery Support Services and Client Outcomes: What do the Data Tell Us? Recovery Community Services Program Grantee Meeting December 14, 2007.
FIVE MINUTES TO MAKE A DIFFERENCE Presentation by: Mark Barnes.
DRUGS OF ABUSE Reynaldo J. Lesaca, M.D. Reynaldo J. Lesaca, M.D.
RAMAR  SINCE 1980, RAMAR HAS BEEN A VITAL PART OF RECOVERY FOR CHRONICALLY ADDICTED RECOVERY FOR CHRONICALLY ADDICTED INDIVIDUALS IN NEED IN SUMMIT COUNTY.
1 Kennedy Roberts Senior Medical Officer and Clinical Lead North Cluster Glasgow Addiction Services Community Addiction Teams What are the challenges for.
The COMBINE Study: Design and Methodology Stephanie S. O’Malley, Ph.D. for The COMBINE Study Research Group JAMA Vol. 295, , 2006 (May 3 rd.
CJ411-Seminar 8 What are the major treatment strategies currently used for drug and alcohol abuse?
Introduction Introduction Alcohol Abuse Characteristics Results and Conclusions Results and Conclusions Analyses comparing primary substance of abuse indicated.
Introduction Results and Conclusions On demographic variables, analyses revealed that ATR clients were more likely to be Hispanic and employed, whereas.
Table 1. Prediction model for maximum daily dose of buprenorphine-naloxone in a 12-week treatment condition Baseline Predictors Maximum Daily Dose Standardized.
1 Session 3 Treatment and Recovery Treatment and Recovery.
بسم الله الرحمن الرحيم. Adult Hodgkin’s Lymphoma in the Eastern Part of Libya Dr. M.Mangoush, R. Nafo, S.Kardah, M.Letaiwish, S.Kardah, F.Bodabous, S.Ebkhatra.
Introduction Results and Conclusions Comparisons of psychiatric hospitalization rates in the 12 months prior to and after baseline assessment revealed.
Principles of Effective Drug Addiction Treatment Health 10 The Truth About Drugs Ms. Meade.
J. Aaron Johnson, PhD 1 and J. Paul Seale, MD 2 1 Institute of Public and Preventive Health and Department of Psychology, Georgia Regents University, Augusta,
60 Ferebee Enterprises International, LLC Global Female Empowerment o/ c
Vivitrol (Naltrexone) Treatment for opioid addiction.
Substance Abuse By: Joe Gonzalez & Danielle Lyner.
CLINICAL EFFICACY STUDY OF BACLOFEN IN REDUCING ALCOHOL CONSUMPTION IN HIGH RISK DRINKERS Study title: Alcohol Treatment : A Pragmatic Randomized, Double-blind.
Seizure Incidence Associated with Bupropion Dosing Errors Reported to a Local Poison Center William Eggleston, PharmD 1 and Ross W. Sullivan, MD 1,2 1.
PSY 425 Week 2 Individual Drug Profile Paper To purchase this material click on below link
Center for Studies of Addiction, University of Pennsylvania, USA
Background and Objectives
Generalized Logit Model
Michael E. Levin, Jacqueline Pistorello,
Ch. 17 Preventing Drug Abuse Section 4 Choosing to be Drug Free
Clinical Opiate Withdrawal – Symptom Management Protocol
Levels of Care Continuum of Care ASAM Patient Placement Criteria (PPC)
Hatch-Maillette, M. 1, Calsyn, D. A1,2, Doyle, S. 1, Woods, A
Medication-Assisted Therapy at Coleman Profession Services
William Eggleston, PharmD1, Nicholas Nacca, MD3, and Jeanna M
Michael L. Parchman, MD, MPH
Alcohol, Other Drugs, and Health: Current Evidence
24 hour levodopa-carbidopa intestinal gel may reduce “unresponsive” freezing of gait and falls in Parkinson’s disease Florence CF Chang, David S Tsui,
L.S. Remy1, G. Woody2, K. Lynch2, K. M. Kampman2
Community ART delivery models for high patient’s retention and good
Babson, et al., in progress Isabella Romero
Analysis of Safety and Efficacy of Dexmedetomidine as Adjunctive Therapy for Alcohol Withdrawal in ICU Vincent Rizzo MD MBA FACP Ricardo Lopez MD FCCP.
Treatments for Addiction
Alcohol, Other Drugs, and Health: Current Evidence May-June, 2018
Peaceful Spirit Treatment Center
Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS I)
administration (single dose, 5 mg) in six healthy male volunteers.
2018 Delaware State Epidemiological Profile
A single centre experience of febrile neutropenia rates in long acting compared with short acting GCSF preparations in breast cancer patients Dr Rebecca.
MS Relapse Management: Team Approaches Colleen Harris MN NP MSCN
Results: Specific Aim 2 (cont.)
Vision Transformative collaboration that fosters resilient self-sustaining Recovery Communities. Mission To develop and sustain measurable solutions that.
Our House Addiction Recovery Center
The relationship between incarceration and opioid addiction treatment
NAD+ NEURO RECOVERY PROGRAM
Medically assisted treatment
Medication Assisted Treatment of Opioid Use Disorder
Presentation transcript:

Intravenous Administration of Nicotinamide Adenine Dinucleotide Significantly Reduces Self Report Craving Ratings Associated with Opiate and Alcohol Withdrawal *S. L. BROOM1, R. MESTAYER2, E. STULLER3, D. COOK4, J. CARSON2, K. SIMONE2, P. NORRIS2, P. HOTARD2 1Dept Psychol, William Carey Univ., Hattiesburg, MS; 2Springfield Wellness Center, Springfield, LA; 3Stullerresettings, LLC; 4 ABAM.SoberMD,LLC INTRODUCTION RESULTS Introduction: Treatment of substance abuse disorders continues to challenge clinicians and “cravings” for the abused substance are often impediments to sobriety. Nicotinamide Adenine Dinucleotide (NAD) has been used in the past with claims of having anti-craving properties. Previous data from this clinic using a similar formulation of NAD support the use of NAD as a valid treatment for drug cravings. This pilot study retrospectively examined the anti-craving properties of NAD in a group of 60 patients. Additionally, patients were assessed on severity of cravings and relapse episodes at 12-20 months post treatment. * * * * * * * * METHOD The patients were adult males and females with addictions to primarily opiates or alcohol (N=60). Six patients were omitted due to incomplete data. The treatment, Brain Restoration Plus (BR+)TM comprised of IV infusions of NAD as well as vitamins, oral amino acids, NAC and variable PRN medications for an average of 10 consecutive days ranging from 5 to 10 hours daily at a dose range of 500mg-1500mg each day. Self-reported craving ratings (0-10 Scale) were collected on Day 1 (before starting treatment), Day 5, and on Day 10 (last day of treatment). Follow up phone surveys were conducted from 12-20 months post treatment (N= 27). Patients reported severity of cravings (1-5) and number of relapse episodes at the present time. CONCLUSIONS ACKNOWLEDGMENTS NAD is an effective detox treatment for alcohol and opiate addicts as evidenced by a significant reduction in craving ratings. NAD was effective in reducing and maintaining the number of relapse episodes, as well as severity of drug cravings. NAD shows potential as a long-term therapy in maintaining sobriety through minimizing drug cravings and preventing relapse. Thank you to Springfield Wellness Center for providing patient data. Thank you to William Carey University for providing a Professional Development Grant in support of this project.

*